Multiple Myeloma

Multiple myeloma treatment has been revolutionized by proteasome inhibitors, immunomodulatory agents, anti-CD38 monoclonal antibodies, and CAR-T cell therapies. Bispecific antibodies and next-generation agents continue to improve outcomes in relapsed/refractory disease.

Approved drugs, investigational agents, and relevant clinical trials for this disease area.

Approved Drugs for Multiple Myeloma

• Daratumumab (Darzalex) — Monoclonal Antibody
• Isatuximab (Sarclisa) — Monoclonal Antibody
• Bortezomib (Velcade) — Proteasome Inhibitor
• Carfilzomib (Kyprolis) — Proteasome Inhibitor
• Ixazomib (Ninlaro) — Proteasome Inhibitor
• Lenalidomide (Revlimid) — Immunomodulatory Agent
• Pomalidomide (Pomalyst) — Immunomodulatory Agent
• Thalidomide (Thalomid) — Immunomodulatory Agent
• Dexamethasone (Decadron) — Corticosteroid
• Elotuzumab (Empliciti) — Monoclonal Antibody
• Selinexor (Xpovio) — Other
• Ciltacabtagene autoleucel (Carvykti) — Other
• Idecabtagene vicleucel (Abecma) — Other
• Talquetamab (Talvey) — Other
• Teclistamab (Tecvayli) — Monoclonal Antibody